BACKGROUND: Erenumab, the first-in-class fully human monoclonal antibody 
targeting the calcitonin gene-related peptide receptor, was shown to be 
efficacious and safe for the prophylactic treatment of migraine in adults in 
randomized clinical trials. Large-scale, real-world evidence in multi-centre 
settings is still needed to confirm these results. Erenumab patient profiles 
outside clinical trials and physicians' treatment patterns, as well as data from 
patients treated in Germany, a severely impacted population, are not published 
yet.
METHODS: TELESCOPE was a multi-centre survey gathering real-world data from 45 
German headache centres between July 2019 and December 2019. The project 
consisted of two parts. In the first part, treating physicians shared their 
experiences on current erenumab treatment with regard to patient profiles, 
treatment patterns and treatment responses. In the second part, a retrospective 
chart review was conducted of 542 migraine patients treated with erenumab for at 
least three months. Treatment responses focused on various aspects of patients' 
quality of life.
RESULTS: The analysis of 542 patients' charts revealed that three-month 
treatment with erenumab significantly reduced monthly headaches, migraine and 
acute medication days. Furthermore, headache intensity and frequency were 
reduced in over 75 % and accompanying aura in 35 % of patients. The clinical 
global impression scale revealed a general improvement in 91 % of patients. 
According to the treating physicians' professional judgement, 83 % of patients 
responded to erenumab and 80 % were satisfied with the treatment. Physicians 
evaluated restricted quality of life, the number of monthly migraine days and 
previous, prophylactic treatments as the main components of the current patient 
profile for monoclonal antibody recipients. Based on the assessment of 
physicians, erenumab reduced migraine symptoms in 65 % and increased quality of 
life in more than 75 % of their patients.
CONCLUSIONS: TELESCOPE confirms positive treatment responses with erenumab shown 
in clinical trials in a real-world multi-centre setting. The results show 
consistently positive experiences of physicians utilizing erenumab in clinical 
practice and underline that therapy with this monoclonal antibody is effective 
in migraine patients, particular in those, who have failed several prophylactic 
therapies.